Gilead Sciences, Inc. (GILD)

In the past six months, Gilead Sciences' stock price has increased by over 12%. The company's Q1 2026 financial results showed better-than-expected revenue and adjusted EPS, with total product sales reaching $6.9 billion, a 5% year-over-year increase. HIV sales were a primary driver, up 10% year-over-year, with strong demand for Biktarvy and significant growth in the U.S. PrEP business. Oncology product sales also increased by 7% year-over-year. Despite the strong sales performance, the stock declined by 1.64% in after-hours trading following the Q1 earnings announcement, likely due to investor concerns regarding acquisition-related costs, as the company lowered its full-year 2026 adjusted EPS guidance. Gilead has been engaged in a significant M&A spree targeting oncology and immunology. The company did, however, raise its full-year 2026 product sales guidance to a range of $30.0 billion to $30.4 billion.

Gilead Sciences experiences demand seasonality for its products and services, particularly in the first quarter of the year. Sequential declines in total product sales, HIV sales, and liver disease sales from Q4 2025 to Q1 2026 were "in line with normal first quarter seasonality." These seasonal factors typically include inventory drawdown following year-end builds and shifts in channel mix, which can lead to lower average realized prices for some products. Despite these sequential declines, the underlying demand trends for key therapeutic areas, such as HIV and oncology, have remained strong year-over-year.

Gilead Sciences, Inc. is an American biopharmaceutical company focused on researching, developing, and commercializing medicines for life-threatening diseases, operating within the Healthcare sector, specifically in the Drug Manufacturers - General and Biotechnology industries. The company's core business has historically centered on antiviral drugs for conditions such as HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, and has strategically expanded into oncology and inflammation through acquisitions. Major products include HIV and antiviral therapies like Biktarvy, Truvada, and Descovy; liver disease treatments like Epclusa and Harvoni; oncology and hematology products like Trodelvy and Yescarta/Tecartus; and other products like Veklury for COVID-19.

Gilead Sciences has a global presence with operations in North America, Europe, Asia, South America, Africa, Australia, and the Middle East. Its headquarters are in Foster City, California, USA. In the U.S., it has R&D sites in Oceanside and Santa Monica, manufacturing sites in El Segundo, La Verne, Oceanside, and San Dimas, and corporate offices in Raleigh, NC, and Parsippany, NJ. Internationally, Gilead has a manufacturing site in Cork, Ireland, and corporate offices in countries including China, India, Japan, Korea, Singapore, Taiwan, Argentina, Brazil, Colombia, Israel, Saudi Arabia, Türkiye, and the United Arab Emirates. The company's international region has shown a consistently increasing asset turnover ratio.

Over the past year, no specific negative events significantly impacted Gilead Sciences' brand reputation. The company's reputation is generally associated with its leadership in antiviral medicine, particularly its long-standing contributions to HIV and hepatitis C treatment. Its strategic shift and expansion into oncology, along with a commitment to research and development and sustainability goals, likely contribute positively to its brand image. The company's focus on addressing unmet medical needs also underpins its reputation.

Gilead Sciences is a widely held public company, with institutional investors dominating ownership, accounting for approximately 84.2% of outstanding shares. Major institutional owners include The Vanguard Group, BlackRock, State Street Global Advisors, Fidelity Management & Research Company, Capital World Investors, Dodge & Cox, and Geode Capital Management. Insider ownership is typically under 0.5%.